This study is being done to evaluate the efficacy and safety of an experimental new drug (ELND005). ELND005 is being compared with a placebo in reducing the severity of agitation and aggression in patients with moderate to severe probable Alzheimer's disease.
This study will enroll patients with probable Alzheimer's disease at the moderate to severe stage (Mini-Mental State Examination [MMSE] 10-21, inclusive) with clinically significant agitation/aggression.
ELND005 is administered orally in a fixed dosing regimen for 12 weeks. During the treatment period, clinical visits will be conducted at weeks 2, 4, 8, and 12/early termination (ET). Telephone contacts will be made at Weeks 1, 3, 6, and 10.
Barbara Cray Lokaitis, BA, CCRP Senior Clinical Trials Coordinator 217.545.9737 firstname.lastname@example.org
Tom Ala, MD